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Abstract
The therapeutic potential of cisplatin, one of the most active and widely
used anticancer drugs, is severely limited by the occurrence of cellular
resistance. In this study, using budding yeast Saccharomyces cerevisiae as
a model organism to identify novel drug resistance genes, we found that
disruption of the yeast gene SKY1 (serine/arginine-rich protein-specific
kinase from budding yeast) by either transposon insertion or one-step
gene replacement conferred cellular resistance to cisplatin. Heterologous
expression of the human SKY1 homologue SRPK1 (serine/arginine-rich
protein-specific kinase) in SKY1 deletion mutant yeast cells restored cis-
platin sensitivity, suggesting that SRPK1 is a cisplatin sensitivity gene, the
inactivation of which could lead to cisplatin resistance. Subsequently, we
investigated the role of SRPK1 in cisplatin sensitivity and resistance in
human ovarian carcinoma A2780 cells using antisense oligodeoxynucle-
otides. Treatment of A2780 cells with antisense oligodeoxynucleotides
directed against the translation initiation site of SRPK1 led to down-
regulation of SRPK1 protein and conferred a 4-fold resistance to cisplatin.
The human SRPK1 gene has not been associated with drug resistance
before. Our new findings strongly suggest that SRPK1 is involved in
cisplatin-induced cell kill and indicate that SRPK1 might potentially be of
importance for studying clinical drug resistance.
Introduction
Cisplatin is one of the most widely used anticancer drugs. Platinum-
based chemotherapy is active against cancers of the lung, ovary,
bladder, head and neck, esophagus, cervix, and endometrium and is
curative for the vast majority of patients with testicular cancer (1).
Unfortunately, cellular resistance to cisplatin, either intrinsic or ac-
quired, is encountered regularly and severely limits the therapeutic
potential of the drug (2). A better understanding of the cellular
mechanisms of cisplatin sensitivity and resistance could lead to the
development of effective specific biological and pharmacological
intervention and thus to better treatment results with regard to long-
term survival. Molecular pathways leading to cisplatin resistance need
to be defined in detail, which will be largely sustained by the identi-
fication and characterization of genes regulating cisplatin sensitivity.
Multiple mechanisms by which cells may overcome the cytotoxic
action of cisplatin have been identified in vitro. These include de-
creased intracellular drug accumulation, inactivation by glutathione or
metallothioneins, aberrations in repair, enhanced tolerance, and de-
fects in pathways modulating cell death (2–4). Despite the many
potentially important resistance mechanisms that have been identified
in vitro, hardly any data demonstrate correlations between presently
known in vitro mechanisms of cisplatin resistance and clinical out-
come. Apparently, these processes do not fully account for the ob-
served in vivo unresponsiveness of particular tumors to platinum-
based chemotherapy. Therefore, additional cisplatin resistance
mechanisms for which the genes involved have yet to be identified
may exist.
We used the budding yeast Saccharomyces cerevisiae as a model
system to study drug sensitivity and resistance (5). In this study, we
performed a genome-wide screen to identify and characterize novel
cisplatin sensitivity genes, and we found that disruption of the yeast
YMR216C locus corresponding to the SKY1 (SR3 protein-specific
kinase from budding yeast) gene conferred cellular resistance to
cisplatin. We demonstrate that down-regulation of the human Sky1p
homologue SRPK1 (SR protein-specific kinase) by antisense ODNs in
human ovarian carcinoma cells also confers cisplatin resistance. This
is the first report in which SKY1 and SRPK1 are associated with
alterations in cisplatin sensitivity, and our findings indicate that
SRPK1 might potentially be of importance for studying clinical drug
resistance.
Materials and Methods
Generation of Cisplatin-resistant Yeast Mutants. Yeast cells were cul-
tured on complete YNB medium (Difco Laboratories, Detroit, MI) at 30°C as
described previously (5). Cisplatin-sensitive S. cerevisiae strain MGSC131 (6) was
transformed with a yeast genomic mini-Tn3::lacZ::LEU2 transposon insertion
library (7), referred to as 35 (kindly provided by Dr. P. B. Ross-Macdonald, Yale
University, New Haven, CT), by means of a high-efficiency protocol. Transfor-
mants were selected on complete YNB medium plates lacking leucine. Leucine-
proficient S. cerevisiae cells were replated at a density of 104 cells/94-mm dish on
selective YNB medium plates containing 4 g/ml cisplatin [Platosin; cis-diam-
minedichloroplatinum(II); Pharmachemie, Haarlem, the Netherlands]. Colonies
surviving this one-step drug selection were picked and retested for cisplatin
resistance in semiquantitative spot assays and quantitative clonogenic survival
assays as described previously (5). Inverse PCR (8) was used to obtain sequences
flanking the transposon elements. PCR products were purified and sequenced
using transposon-specific primers (7). A gene-specific SKY1 disruption was gen-
erated in strain MGSC283 (an isogenic ura3-1 derivative of MGSC131) by
one-step gene replacement performed as described by Rothstein (9), which yielded
MGSC-sky1 cells. The construct used in the one-step gene replacement proce-
dure was made using primers SKY1-5A (5-GTA-AGA-AAG-CTG-GGA-TGG-
GGC-CAC-TTC-TCA-TCT-TTG-ACA-GCT-TAT-CAT-C-3) and SKY1-3 (5-
CGG-AAC-CAC-TCC-CGT-ACA-ACT-CTC-TAT-CAG-GTA-CCC-ACT-
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CGT-GCA-CCC-3). A probe hybridizing to the 0.5-kb 5 SpeI-HindIII SKY1
fragment was used to confirm successful disruption by Northern blotting. Se-
quences were analyzed using the Saccharomyces Genome Database. Database
entries used for amino acid comparisons between Sky1p and its human counter-
part, SRPK1, were RefSeq accession number NP_013943 and Protein Information
Resource accession number S45337, respectively.
Construction of Expression Plasmids. A 2.3-kb SKY1 PCR product was
ligated into the low-copy S. cerevisiae expression vector pYCTEF, which
consists of the 4.5-kb PvuII backbone fragment from centromeric plasmid
YCplac22 (10) and the 1.0-kb PvuII fragment from p424TEF (11), containing
the constitutive translation elongation factor 1 promoter. The PCR product
was generated using primers SKYex-5 (5-ATA-GTG-GAT-CCT-GGT-ATA-
AAT-AGA-CAC-CCC-C-3) and SKYex-3 (5-CTA-ACC-TCG-AGA-GGG-
CAA-AAT-AAA-GGT-ATA-AAG-G-3). The full-length human SRPK1 cod-
ing region, homologous to SKY1, was kindly provided by Drs. X-D. Fu and
H-Y. Wang (University of California at San Diego, La Jolla, CA), and
dnSRPK1 (12) was made available by Drs. X-D. Fu and J-H. Ding (University
of California at San Diego). Both constructs were also cloned into the pYCTEF
expression vector, enabling heterologous expression in yeast.
Treatment of Cells with Antisense ODNs. The human ovarian carcinoma
A2780 cell line was obtained from the American Type Culture Collection
(Manassas, VA), and maintained in HEPES-buffered RPMI 1640 supple-
mented with 10% fetal bovine serum (Life Technologies, Inc., Rockville, MD)
in a humidified incubator at 37°C with 8.5% CO2. Morpholino phosphorodia-
midate antisense ODNs directed against the translation initiation site of SRPK1
(referred to henceforth as AS-SRPK1; sequence, 5-CAT-GGT-GAG-ACC-
CAA-CAA-AAG-CAG-G-3), control random antisense ODNs (referred to
henceforth as NS; sequence, 5-CCT-CTT-ACC-TCA-GTT-ACA-ATT-TAT-
A-3), and control antisense ODNs with four mispairs distributed along the
sequence (referred to henceforth as MIS; sequence, 5-CAT-CGT-GTG-ACC-
CAA-CAA-TAG-CTG-G-3; mismatches are shown in bold) were purchased
from Gene Tools (Corvallis, OR). Incubation of A2780 cells with ODNs was
performed using the manufacturer’s Special Delivery protocol. Cisplatin sen-
sitivity of ODN-treated A2780 cells was determined by MTT assay (13).
Briefly, the cells were seeded in 96-well tissue culture plates. The next day, the
culture medium was replaced by medium containing ODNs and 0.6 M
ethoxylated polyethylenimine delivery agent but lacking serum, and the cells
were incubated at 37°C with 8.5% CO2 for 3 h. Subsequently, the medium was
exchanged with standard culture medium containing serum, as described
above. After 16 h, cisplatin was added at a dose range of 0–24 M, and the
cells were allowed to grow for another 72 h. Growth inhibition was determined
by the use of MTT (Sigma-Aldrich, Zwijndrecht, the Netherlands) as described
by Perez et al. (13).
Statistical Analysis. Relationships between cisplatin concentration and
cisplatin-induced cytotoxicity were evaluated using Siphar version 4.0 soft-
ware (InnaPhase, Philadelphia, PA) and the Number Cruncher Statistical
System version 5.X package (Dr. J. L. Hintze, University of Utah, East
Kaysville, UT). Data were fitted to a sigmoidal maximum effect (Emax) model
based on the modified Hill equation, as follows: E  E0  Emax  [(C)/
(C  EC50)]. In this equation, E0 is the “no drug” effect, Emax is the
maximum drug effect, C is the drug concentration to which cytotoxicity is
related, EC50 is the drug concentration predicted to result in half-maximal
cytotoxicity, and  is the Hill constant describing the sigmoidicity of the curve.
The difference in EC50 between two cytotoxicity tests was evaluated statisti-
cally using a two-tailed (unpaired) Student’s t test.
Immunofluorescence Detection and Western Blot Analysis of SRPK1.
After 3 h of incubation with 5.6 M ODNs as described above, followed by
recovery in standard culture medium, a monolayer of A2780 cells was depos-
ited on slides in a Cytospin 2 Cytocentrifuge (Shandon Inc., Pittsburgh, PA) at
750 rpm for 10 min. Cells were fixed in methanol:acetone (1:1) at 20°C for
10 min, rehydrated in PBS at room temperature for 15 min, and then blocked
in blocking buffer (10% rabbit serum, 1% goat serum, and 1% normal human
serum in PBS) at room temperature for 15 min. Next, they were incubated at
room temperature for 45 min with primary monoclonal anti-SRPK1 (mouse
IgG1; 1:50 dilution of the 250 g/ml stock purchased from BD Transduction
Laboratories, Lexington, KY) or nonspecific mouse monoclonal IgG1 (ICN/
Cappel, Costa Mesa, CA) at the same final concentration, washed three times
with PBS, and developed at room temperature for 30 min with secondary
FITC-conjugated goat antimouse IgG (1:50 dilution of the 1 mg/ml stock
obtained from Nordic, Tilburg, the Netherlands). Finally, the slides were
washed three times in PBS and mounted in VECTASHIELD medium contain-
ing 1 g/ml 4,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame,
CA) for examination under a Leica DMR fluorescence microscope with the
CGH photoimaging system (Leica Microsystems, Wetzlar, Germany). For
Western blotting, A2780 cells were incubated similarly, and total protein was
isolated by adding SDS-loading buffer to cell pellets and boiling the samples
for 3 min. Western blots were blocked in PBS containing 0.2% Tween 20 and
5% Protifar (Nutricia, Zoetermeer, the Netherlands) at 37°C for 1 h and then
incubated with a 1:2000 dilution of mouse monoclonal anti-SRPK1 at 4°C for
16 h. SRPK1 was visualized using horseradish peroxidase-linked goat anti-
mouse IgG (1:4000 dilution of the 400 g/ml stock purchased from Santa Cruz
Biotechnology, Santa Cruz, CA) and SuperSignal West Pico chemiluminescent
substrate (Pierce, Rockford, IL). Blots were then stripped in 63 mM Tris (pH
6.8), 0.002% SDS, and 114 mM -mercaptoethanol at 56°C for 45 min and
reincubated as described above with a 1:5000 dilution of mouse monoclonal
anti--actin (Sigma-Aldrich) as first antibody.
Results and Discussion
Disruption of the SKY1 Gene in Yeast Induces Cisplatin
Resistance. In this study, we used the budding yeast S. cerevisiae as
a model system to search for novel genes that, upon disruption, confer
cellular resistance to the commonly applied anticancer drug cisplatin.
A yeast genomic mini-Tn3::lacZ::LEU2 transposon insertion library
(7), referred to as 35, was introduced into S. cerevisiae cells.
Transformation originates from homologous recombination between
yeast DNA sequences flanking the transposon and endogenous
genomic sequences, leading to replacement of the original genomic
copy with the mutagenized version (9). A cisplatin-sensitive yeast
strain referred to as MGSC131, which displays a steep dose-response
curve to the drug (5, 6), was used as recipient. Untransformed
MGSC131 cells seeded on cisplatin-containing YNB medium plates
did not yield any colonies, even after prolonged incubation. In con-
trast, when 3  105 transformants of library 35 were plated under
identical conditions, 31 colonies surviving the one-step drug selection
grew within 3–6 days. Upon verification of the resistance phenotypes
of the colonies derived from this genome-wide yeast screening ap-
proach, we selected nine strains that showed a similar cisplatin resist-
ance level for further characterization. Southern blotting using a
transposon-specific probe revealed that each strain contained one
single transposon insertion (data not shown). The sites flanking the
transposons (i.e., the loci that had been disrupted) could thus be
identified directly by means of inverse PCR (8), followed by sequenc-
ing of the respective products. Sequences of 50–60 bp on either side
of the transposon were obtained, and the insertion sites were defined
by comparison with public S. cerevisiae databases.
Most prominently, the YMR216C locus corresponding to the SKY1
gene (14) turned out to be disrupted in at least five transposon-
containing cisplatin-resistant yeast strains, referred to as 35-2,
35P-1, 35P-3, 35P-4, and 35P-5. At least three strains (35-2 or
35P-1, 35P-3 or 35P-4, and 35P-5) appeared to contain differ-
ent insertions in the same gene, as judged by the sizes of the PCR
products obtained (Fig. 1a). In the remaining transposon-containing
cisplatin-resistant yeast strains, other loci had been disrupted, as will
be described elsewhere.4 In a quantitative clonogenic survival assay,
strains 35-2, 35P-1, 35P-3, 35P-4, and 35P-5 were 4-fold
cisplatin resistant as compared with parental MGSC131-SKY1 cells.
Fig. 1b shows a typical cisplatin sensitivity profile of the transposon-
derived sky1 transformant 35-2 as compared with untransformed
isogenic SKY1 cells.
The observed cisplatin-resistant phenotype of the transposon-con-
taining transformants could, in principle, have arisen from unrelated
4 Manuscript in preparation.
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mutations acquired during the screening procedure (i.e., cisplatin-
induced mutations leading to resistance) rather than library-derived
gene disruption. To address this issue, PCR-generated one-step gene
replacement constructs (9) were used to disrupt the SKY1 gene from
the S. cerevisiae genome independently. Successful disruption was
confirmed by PCR (data not shown) and Northern blotting (Fig. 1b,
inset), and possible cisplatin resistance of the replacement-derived
sky1 mutant (MGSC-sky1) was monitored. Indeed, the cisplatin
sensitivity profile appeared to be similar to that of the original trans-
poson-containing sky1 strains (Fig. 1b), i.e., MGSC-sky1 cells
were 4-fold cisplatin-resistant.
Subsequently, we reintroduced the SKY1 gene into the sky1 de-
letion mutant cells. For this purpose, the SKY1 open reading frame
was cloned into yeast expression vector pYCTEF, and the resulting
plasmid was transformed into MGSC-sky1 cells. The transformants
became as sensitive to cisplatin as the original MGSC131-SKY1
strain, whereas transformation with the empty vector alone left the
resistance of the MGSC-sky1 cells completely unaffected (Fig. 1b).
Our findings clearly demonstrate that the cisplatin resistance, which
was observed originally, was linked to disruption of the SKY1 gene.
Moreover, the data suggest that Sky1p is involved in the cytotoxicity
of cisplatin, i.e., that SKY1 might be regarded as a cisplatin sensitivity
gene.
Heterologous Expression of the Human Homologue SRPK1
Restores Cisplatin Sensitivity in sky1 Mutant Yeast. Database
analysis revealed that SKY1 has a human homologue, which encodes
the SR protein-specific kinase SRPK1. SR protein-specific kinases
and the SR proteins that they phosphorylate are thought to be key
regulators of RNA processing and, in mammalian cells, alternative
splicing through multiple mechanisms (14, 15). The predicted
polypeptide sequence encoded by the human SRPK1 cDNA shares
35% identity over 644 amino acids to Sky1p. Notably, SRPK1 and
Sky1p also share structural homology: their kinase domains are in-
terrupted by a unique spacer sequence. Because several data suggest
strongly that Sky1p and SRPK1 perform homologous functions in
vivo (14, 16), we tested SRPK1 for its ability to complement the
cisplatin resistance phenotype of S. cerevisiae sky1 cells. SRPK1
was cloned into yeast expression vector pYCTEF and transformed
into MGSC-sky1 mutant cells. Heterologous RNA expression was
confirmed by Northern blotting (Fig. 2, inset) using a PCR-generated
probe specific for the spacer domain of SRPK1 (14). In MGSC-sky1
yeast cells the cisplatin resistance phenotype appeared to be largely
reversed by introduction of the human SRPK1 gene, as was the case
when the yeast SKY1 gene was reintroduced. In contrast, MGSC-
sky1 cells transformed with a construct encoding a well-established
dominant-negative kinase-inactive mutant (K109M) of SRPK1
(dnSRPK1; Refs. 12 and 16) were still cisplatin resistant (Fig. 2).
Apparently, SRPK1 can functionally substitute SKY1 in S. cerevisiae
cells and can therefore be considered a cisplatin sensitivity gene as
well. To our knowledge, SKY1 and SRPK1 have not been previously
associated with cisplatin sensitivity or resistance. The observation that
dnSRPK1 (encoding a kinase-inactive protein) could not substitute
SKY1 suggests that the kinase function of SR protein-specific kinases
is essential for the cytotoxicity of cisplatin in yeast.
Antisense Experiments. Because SRPK1 was able to act as a
cisplatin sensitivity gene in S. cerevisiae cells, we assessed whether it
also functions as a gene that is necessary for proper cisplatin-induced
cell kill in human cells. Therefore, we designed experiments in which
we could monitor the effects of SRPK1 inactivation by antisense
ODNs on cisplatin sensitivity in human cells. First, we established the
effect of AS-SRPK1 on SRPK1 protein expression levels in ovarian
carcinoma A2780 cells by immunofluorescence. In untreated A2780
cells, we found SRPK1 expression in both the cytoplasm and nuclear
speckles (Fig. 3, a and b), as demonstrated previously (17). Treatment
Fig. 1. Disruption of yeast SKY1 induces resistance to cisplatin. a, S. cerevisiae cells
were transformed with yeast genomic mini-Tn3::lacZ::LEU2 transposon insertion library
35, and on random disruption and cisplatin selection, genomic DNA was isolated from
cisplatin-resistant yeast strains. Inverse PCR was then performed using transposon-
specific outward-directed primers. An agarose gel loaded with the respective PCR
products derived from strains 35-2, 35P-1, 35P-3, 35P-4, and 35P-5 is shown. The
product size for strains 35-2 and 35P-1 was 750 bp, the product size for strains
35P-3 and 35P-4 was 650 bp, and the product size for strain 35P-5 was 350 bp
(as judged by the molecular masses of the marker in the left lane), indicating that the
transposon resided in at least three different positions. Sequencing of these PCR products
revealed that the SKY1 gene had been disrupted. b, cisplatin sensitivity profiles of S.
cerevisiae wild-type MGSC131-SKY1 cells (f), transposon-derived isogenic sky1
mutant 35-2 cells (E), replacement-derived MGSC-sky1 cells (), and MGSC-sky1
cells transformed with the constitutive low-copy yeast expression vector pYCTEF (‚) or
pYCTEF-SKY1 (F). Percentage survival (colony formation) at each concentration of
cisplatin is expressed relative to untreated control cells (100%). Means of three independ-
ent experiments performed in triplicate are shown; bars , SD. Bars are sometimes masked
by the data point symbols. Northern blotting (inset) using an NH2-terminal SKY1 probe
confirmed that whereas MGSC131-SKY1 cells do express the SKY1 gene (Lane 1), SKY1
mRNA was absent from MGSC-sky1 cells (Lane 2). The same procedure confirmed the
expression of SKY1 on introduction of pYCTEF-SKY1 into MGSC-sky1 cells (Lane 3).
Fig. 2. Restoration of cisplatin sensitivity in sky1 deletion mutant yeast by the human
homologue SRPK1. Cisplatin sensitivity profiles of wild-type MGSC131-SKY1 (f),
deletion mutant MGSC-sky1 (), and MGSC-sky1 transformed with pYCTEF-SRPK1
(Œ) or pYCTEF-dnSRPK1 (‚) are shown. Percentage survival (colony formation) at each
concentration of cisplatin is expressed relative to untreated control cells (100%). Means
of at least two independent experiments performed in triplicate are shown; bars , SD.
Inset, RNA was isolated from S. cerevisiae MGSC-sky1 cells transformed with
pYCTEF-SRPK1 or pYCTEF-dnSRPK1, and Northern blotting using an SRPK1-specific
probe was used to confirm the heterologous expression of the human SKY1 homologue
SRPK1 in its wild-type and dominant-negative form (Lanes a and b, respectively).
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of A2780 cells with control antisense ODNs, NS, or MIS had no
detectable effect on SRPK1 protein expression levels or subcellular
localization (Fig. 3, e–h). In contrast, expression of the SRPK1
protein was largely decreased after treatment of A2780 cells with
specific AS-SRPK1 (Fig. 3, c and d). Incubation with AS-SRPK1
almost completely abolished the nuclear staining of SRPK1 protein
(Fig. 3, c and d) as compared with NS or MIS (Fig. 3, e–h), whereas
cytoplasmic staining was reduced to the background level detected
using a nonspecific antibody (data not shown). Notably, the anti-
SRPK1 monoclonal antibody used in these experiments is highly
specific: on Western blots, it recognized a single band of 92 kDa
which is in agreement with the relative molecular mass of the SRPK1
protein, as published by Gui et al. (15). Furthermore, Western blotting
experiments confirmed the specific down-regulation of SRPK1 ex-
pression by AS-SRPK1: there was a marked decrease in the level of
SRPK1 protein detected on incubation of A2780 cells with AS-
SRPK1 as compared with NS or MIS (Fig. 3i).
Now that we had shown that AS-SRPK1 was able to specifically
down-regulate SRPK1 protein expression, we tested it for its effects
on cisplatin sensitivity. First, we determined the optimum dose for
AS-SRPK1 treatment. A2780 cells were incubated with increasing
concentrations of AS-SRPK1 (1.4, 2.8, 5.6, and 11.2 M) at a fixed
dose of cisplatin (6 M), and survival was estimated by monitoring
cell proliferation in MTT assays (Fig. 4, inset). For the ODN dose
range tested, the optimum concentration for reduction of cisplatin-
induced growth inhibition appeared to be 5.6 M AS-SRPK1 (Fig. 4,
inset). Subsequently, we determined the shift in EC50 value (i.e., the
cisplatin concentration predicted to result in half-maximal cytotoxic-
Fig. 3. Effect of antisense ODN treatment on
SRPK1 protein expression, and specificity of the
antibody used. Human A2780 cells were either left
untreated (a and b) or treated with specific AS-
SRPK1 (c and d), NS (e and f), or MIS (g and h).
Expression and localization of SRPK1 were visu-
alized by indirect immunofluorescence staining of
cytospins using a mouse monoclonal anti-SRPK1
antibody followed by FITC-conjugated secondary
antibody (a, c, e, and g). The slides were also
stained with 4,6-diamidino-2-phenylindole to vi-
sualize the nuclei (b, d, f, and h). Arrows indicate
nuclear speckles, which were clearly discernible in
slides obtained from untreated or control-treated
cells (a, e, and g). In cytospins from cells treated
with specific AS-SRPK1 (c), FITC staining was
virtually absent from the nucleus. i, Western blot
analysis of total protein preparations. A2780 cells
were treated with specific AS-SRPK1, NS, or MIS,
as indicated below the lanes, and 6  103 cell
equivalents/lane were loaded. SRPK1 was visual-
ized using primary mouse monoclonal anti-SRPK1,
secondary horseradish peroxidase-linked goat anti-
mouse IgG antibodies, and chemiluminescence
staining (left panel). To confirm that equivalent
amounts of protein were present in each lane, the
blot was stripped and reincubated with mouse
monoclonal anti--actin as first antibody (right
panel). Apparent molecular masses of the marker
are indicated in kDa. SRPK1 and -actin migrated
at 92 and 42 kDa, respectively.
Fig. 4. Down-regulation of SRPK1 by antisense ODN treatment induces resistance to
cisplatin in human cells. Survival was determined by monitoring the proliferation of
A2780 cells on ODN treatment and cisplatin incubation, using MTT assay. The optimum
AS-SRPK1 concentration for reduction of cisplatin-induced cytotoxicity was determined
using increasing concentrations of specific AS-SRPK1 at 6 M cisplatin (inset). Cisplatin
sensitivity profiles of cells treated with NS (f), MIS (F), or delivery agent alone (Œ)
versus cells treated with specific AS-SRPK1 () were then determined at the optimal
dose of 5.6 M ODNs. Percentage survival at each concentration of cisplatin is expressed
relative to control cells that had been incubated in the absence of cisplatin (100%). A
typical experiment (of three performed) carried out in triplicate is shown; bars, SE. The
cisplatin concentrations predicted to result in half-maximal cytotoxicity (EC50s), based on
the modified Hill equation fitted to the data, are indicated below the curves. Ps indicate
the significance of the differences in EC50s between AS-SRPK1 treatment and the
appropriate controls.
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ity) at a fixed dose of 5.6 M AS-SRPK1, as compared with the same
dose of NS or MIS, by MTT assay. Repeatedly, AS-SRPK1 induced
a 3- to 4-fold cisplatin resistance in A2780 cells, as evaluated against
incubation with NS or MIS. Notably, the growth rate of A2780 cells
in the absence of cisplatin was not decreased after treatment with
AS-SRPK1, as compared with NS or MIS (data not shown). A typical
experiment (of three performed) is shown in Fig. 4; whereas incuba-
tion with NS, MIS, or delivery agent alone resulted in similar EC50
values (1.5  0.19, 2.2  0.63, and 2.2  0.30 M cisplatin,
respectively), AS-SRPK1 treatment led to a 3- to 4-fold increase in
EC50 (6.3  0.70 M cisplatin). Statistical analysis comparing NS,
MIS, or delivery agent only versus AS-SRPK1 treatment indicated
that the differences in EC50 were significant at P 	 0.0001, as
estimated by Student’s t test. It can thus be concluded that down-
regulation of SRPK1 protein by specific antisense ODNs rendered
A2780 cells resistant to cisplatin, i.e., SRPK1 may function as a
cisplatin sensitivity gene in this human ovarian carcinoma cell line.
Mechanistic Aspects and Implications for Clinical Studies. To
characterize the specificity and underlying mechanisms of the ob-
served resistance of sky1 yeast cells, other DNA-damaging agents,
including platinum-based drugs, will be used in future studies. Be-
cause, in our hands, sky1 strains showed normal growth character-
istics,5 and the growth rate of human A2780 cells was not decreased
by incubation with specific ODNs, the cisplatin-resistant phenotypes
were obviously not caused simply by distorted growth. Because we
did not detect altered levels of yeast SKY1 RNA on cisplatin treat-
ment,5 the gene is probably not regulated by cisplatin at the transcrip-
tional level. Sky1p (and SRPK1) activity could be regulated instead
by autophosphorylation or posttranslational modification by upstream
components.
As stated above, our data suggest that the kinase function is
essential to the involvement of SR protein-specific kinases in the
cytotoxicity of cisplatin. The S. cerevisiae SR protein encoded by
NPL3 has been shown (14) to be phosphorylated by Sky1p both in
vitro and in vivo and shuttles between the nucleus and the cytoplasm
to deliver mRNA and/or proteins. It has been demonstrated (18–21)
that phosphorylation of Npl3p and mammalian SR proteins specifi-
cally modulates their protein-protein and protein-RNA interactions
and localization. Sky1p and SRPK1 may thus be key players in
pathways determining cisplatin sensitivity via mRNA and/or protein
delivery by Npl3p or mammalian SR proteins, respectively.
In future studies, we will assess the relative contribution of path-
ways using SRPK1 to clinical cisplatin sensitivity and resistance. Low
levels of cisplatin resistance are generally believed to be sufficient to
cause lack of clinical responsiveness. Changes of 	2-fold may ac-
count for treatment failure in human ovarian carcinoma xenografts
(22). Interestingly, SRPK1 is highly expressed in testis (23), whereas,
at the same time, testicular germ cell tumors are extremely sensitive
to cisplatin-containing chemotherapy (1). Indeed, constitutive expres-
sion of SKY1 from a high-copy vector clearly made sky1 yeast cells
more sensitive to cisplatin, as compared with an appropriate SKY1
control strain,5, 6 which suggests that SR protein-specific kinases are
cisplatin sensitivity genes in the sense that they are actively involved
in the cytotoxicity of cisplatin. In addition, we found that down-
regulation of SRPK1 with AS-SRPK1 also made NT2 testicular
cancer cells less sensitive to cisplatin, as compared with cells treated
with control MIS.5 Given these observations, we will monitor samples
derived from both ovarian and testicular cancers, which are generally
treated with cisplatin-containing regimens in the clinic (1), for SRPK1
expression and correlation with clinical responsiveness.
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